Spero Therapeutics’ oral antibiotic tebipenem shows Phase 3 success and supports GSK’s NDA resubmission. Click here to read ...
Exelixis, Inc. (NASDAQ:EXEL) Q4 2025 Earnings Call Transcript February 10, 2026 Exelixis, Inc. beats earnings expectations. Reported EPS is $0.94, expectations were $0.77. Operator: Good day, ladies ...
Inside Axial Aero’s workspace, engineering diagrams, motion platforms and lines of code converge with a single aim: to recreate the realities of flight as faith ...
The Company is in Advanced Stages of Commercial U.S. Partnership Discussions for D-PLEX100 Positive FDA Pre-NDA Feedback Supports Rolling NDA Review- Submission Expected to Begin by the End of the Fir ...
Myers' upcoming $30B patent cliff as the Growth portfolio lost significant potential. Read why BMY stock is downgraded to Hold.
Elon Musk calls for amnesty for Epstein victims amid newly released DOJ files, addresses past email exchanges with Jeffrey ...
Q4 2025 Management View CEO Michael Morrissey described 2025 as a “transformational year” with “strong growth across all ...
In Tamil Nadu, Chief Minister M K Stalin affirmed the strength of the DMK-Congress alliance amidst tensions over power-sharing. While Congress seeks cabinet representation, Stalin emphasized continued ...
Lok Sabha Leader of the Opposition (LoP) and Congress MP Rahul Gandhi on Wednesday questioned why industrialist Anil Ambani ...
Exelixis Inc (EXEL) reports robust financial performance with significant growth in US cabo franchise revenues and strategic pipeline developments.